A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Completed · Phase 3
Conditions studied: Esophageal Squamous Cell Carcinoma (ESCC)
In brief
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Key facts
- Study ID
- NCT03430843
- Run by
- BeiGene
- People needed
- 512
- Starts
- 2018-01-26
- Expected to finish
- 2022-12-28
- Last updated by the study team
- 2024-10-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Toledo Clinic Cancer Center — Toledo, Ohio, United States
- Imelda Ziekenhuis Bonheiden — Bonheiden, Belgium
- Cliniques Universitaires Saint Luc — Brussels, Belgium
- Uz Antwerpen — Edegem, Belgium
- University Hospitals Leuven — Leuven, Belgium
- The Second Hospital of Anhui Medical University — Hefei, Anhui, China
- Beijing Friendship Hospital, Capital Medical University — Beijing, Beijing Municipality, China
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital — Fuzhou, Fujian, China
- The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China
- Fujian Cancer Hospital — Fuzhou, Fujian, China
- The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China
- The First Affiliated Hospital, Sun Yat Sen University — Guangzhou, Guangdong, China
- The Sixth Affiliated Hospital, Sun Yat Sen University — Guangzhou, Guangdong, China
- Cancer Hospital of Shantou University Medical College — Shantou, Guangdong, China
- Peking University Shenzhen Hospital — Shenzhen, Guangdong, China
- Affiliated Hospital of Hebei University — Baoding, Hebei, China
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
- The First Affiliated Hospital of Xinxiang Medical University — Xinxiang, Henan, China
- Henan Cancer Hospital — Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China
- Hubei Cancer Hospital — Wuhan, Hubei, China
- Xiangyang Central Hospital — Xiangyang, Hubei, China
- Henry Ford Hospital — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.